---

FDA's Center for Drug Evaluation and Research (CDER), Division of Rheumatology and Transplant Medicine is co-hosting a virtual meeting with the American College of Rheumatology (ACR) on May 17-18, 2022.

The inaugural ACR-FDA Summit will address care, policy, and research-relevant topics, such as assessment of long-term safety, clinical efficacy, and structural outcomes in conjunction with novel study designs and biomarker development in rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

The summit’s interactive, consensus building format will bring together various stakeholders from academia and industry to provide a broad perspective on current clinical development challenges and offer practical means to overcome these challenges.

We invite rheumatologists, physicians, clinicians, healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in clinical research to join.

Workshop Objectives

Upon completion of this activity, participants should be able to:

• Discuss ways to maintain interest in RA and PsA drug development
• Review innovative study designs, including use of novel outcome measures and patient reported outcomes

For more information and to register for the workshop, please visit the event webpage.